Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05833009
Other study ID # 2022-64
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date September 30, 2024

Study information

Verified date January 2023
Source Shanghai Mental Health Center
Contact Jianhua Chen
Phone (+86) 18017311011
Email jianhua.chen@smhc.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial aims to test the effect of acupuncture in patients with schizophrenia-related central obesity. The main question it aims to answer is: • The effect, safety, and maintenance of acupuncture on schizophrenia-related central obesity. Participants will receive acupuncture treatment on purpose acupoints, acupuncture on acupoint peripheries, or fake acupuncture treatment on purpose acupoints for 20 weeks. And they need three follow-up visits during the treatment period and two follow-up visits after treatment. Researchers will compare the waist circumstance of these three groups to see if the purpose acupoints are valid for schizophrenia-related central obesity.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date September 30, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnosis with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders: Fifth Edition); - Continuous use of antipsychotics for more than one year (may be combined with mood stabilizers, antianxiety medications, antidepressants, and benzodiazepines); - Abdominal obesity (central obesity): waist circumference =90cm for men or =85cm for women (Chinese Standard); - All participants and their guardians signed informed consent. Exclusion Criteria: - Had various traditional Chinese medicine or chemical drugs, or acupuncture treatments for central obesity within two weeks before enrollment; - Pregnant or lactating woman; - Organic mental disorders and mental disorders induced by psychoactive and non-addictive substances; - With other diseases affecting their mental state (e.g., chronic obstructive pulmonary disease, coronary heart disease, angina pectoris, stroke, painful joint diseases, severe psychiatric diseases, tumors, and other physical diseases) - Severe liver and kidney insufficiency or other serious diseases of the system; - With a family history of metabolic diseases such as hypertension, diabetes, and hyperlipidemia; - Acupuncture dizziness, needle phobia, and other intolerant acupuncture treatment; - Patients who are not treated according to the regulations, cannot determine the efficacy or have incomplete data affecting the efficacy and safety evaluation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Acupuncture
All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.

Locations

Country Name City State
China Shanghai Huangpu Mental Health Center Shanghai Shanghai
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (4)

Lead Sponsor Collaborator
Shanghai Mental Health Center Shanghai Huangpu Mental Health Center, Shanghai University of Traditional Chinese Medicine, Yueyang Hospital of lntegrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Waist Circumference at 8 weeks, 16 weeks, 20 weeks, 32 weeks, respectively Waist Circumference in centimiter Baseline, 8 weeks, 16 weeks, 20 weeks, 32 weeks
Secondary Change from Baseline Body Weight Index at 8 weeks, 16 weeks, 20 weeks, 32 weeks, respectively weight and height will be combined to report BMI in kg/m^2 Baseline, 8 weeks, 16 weeks, 20 weeks, 32 weeks
Secondary Change from Baseline Hip Circumference at 8 weeks, 16 weeks, 20 weeks, 32 weeks, respectively Hip Circumference in centimiter Baseline, 8 weeks, 16 weeks, 20 weeks, 32 weeks
Secondary Change from Baseline both Blood Pressure at 8 weeks, 16 weeks, 20 weeks, 32 weeks, respectively both Blood Pressure in mm/Hg Baseline, 8 weeks, 16 weeks, 20 weeks, 32 weeks
Secondary Change from Baseline Blood Triglyceride at 16 weeks, 32 weeks, respectively Blood Triglyceride in mmol/L Baseline, 16 weeks, 32 weeks
Secondary Change from Baseline Blood Total Cholesterol at 16 weeks, 32 weeks, respectively Total Cholesterol in mmol/L Baseline, 16 weeks, 32 weeks
Secondary Change from Baseline Blood Low-density Lipoprotein at 16 weeks, 32 weeks, respectively Blood Low-density Lipoprotein in mmol/L Baseline, 16 weeks, 32 weeks
Secondary Change from Baseline Blood High-density Lipoprotein at 16 weeks, 32 weeks, respectively Blood High-density Lipoprotein in mmol/L Baseline, 16 weeks, 32 weeks
Secondary Change from Baseline Blood Glucose at 16 weeks, 32 weeks, respectively Blood Glucose in mmol/L Baseline, 16 weeks, 32 weeks
Secondary Change from Baseline Positive And Negative Syndrome Scale at 8 weeks, 20 weeks, 32 weeks, respectively The Positive And Negative Syndrome Scale is used for valuation of positive symptom, negative symptom and general symptom of patients with schizophrenia. The score range of Positive And Negative Syndrome Scale is 0 to 150. The higher the score, the more severe the psychiatric symptoms. Baseline, 8 weeks, 20 weeks, 32 weeks
Secondary Change from Baseline Clinical Global Impression at 8 weeks, 20 weeks, 32 weeks, respectively The Clinical Global Impression evaluates the severity of ilness, global improvement and efficacy index. The score range of severity of ilness is 0 (none) to 7 (extremly severe). The score range of global improvement is 0 (none) to 7 (seriously deteriorated). The score range of efficacy index is 0 (none) to 4 (effective and no adverse effect). Baseline, 8 weeks, 20 weeks, 32 weeks
Secondary Change from Baseline Personal and Social Performance Scale at 8 weeks, 20 weeks, 32 weeks, respectively The score range of Personal and Social Performance Scale is 1 to 100. The higher score, the better personal and social performance. Baseline, 8 weeks, 20 weeks, 32 weeks
Secondary Change from Baseline Appetite visual analogue scale at 8 weeks, 20 weeks, 32 weeks, respectively The score range of Appetite visual analogue scale is 0 to 10. The higher score, the better appetite. Baseline, 8 weeks, 20 weeks, 32 weeks
Secondary Change from Baseline Treatment Emergent Symptom Scale at 8 weeks, 16 weeks, 20 weeks, 32 weeks, respectively The Treatment Emergent Symptom Scale contains 34 different common adverse effects in psychiatry patients. Each adverse effect can be assessed from three aspects, which are serverity, relationship with medications, and mesurement taken. The score range of serverity is 0 (none) to (servere). The range of relationship with medication is none, basicly (likelihood 10%) , maybe (likelihood 10%-50%), very likely (likelihood 50%-80%), definitely (likelihood over 90%). The score range of measurement taken is 0 (none) to 5 (stop medication). Baseline, 8 weeks, 16 weeks, 20 weeks, 32 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A